Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Donafenib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2023 Primary endpoint (Progression Free Survival (PFS) has been met according to Results published in the Clinical Cancer Research.
15 May 2023 Results assessing the antitumour activity and safety of donafenib in Chinese RAIR-DTC patients published in the Clinical Cancer Research
29 Nov 2021 Status changed from recruiting to discontinued, based on IDMC's recommendations during the interim analysis"the trial has reached the goal of early termination of the trial",the sponsor communicating with CDE,CDE agreed to unblind the trial and submit a NDA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com